Traders purchased shares of Pfizer Inc. (NYSE:PFE) on weakness during trading hours on Thursday. $201.32 million flowed into the stock on the tick-up and $92.94 million flowed out of the stock on the tick-down, for a money net flow of $108.38 million into the stock. Of all equities tracked, Pfizer had the 9th highest net in-flow for the day. Pfizer traded down ($0.08) for the day and closed at $34.80

Several equities analysts have issued reports on PFE shares. Morgan Stanley set a $36.00 target price on Pfizer and gave the company a “neutral” rating in a research note on Monday, May 9th. Vetr upgraded Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.94 target price on the stock in a research note on Monday, June 27th. Deutsche Bank AG reiterated a “buy” rating and issued a $44.00 target price on shares of Pfizer in a research note on Thursday, August 18th. Credit Suisse Group AG reiterated an “outperform” rating and issued a $40.00 target price on shares of Pfizer in a research note on Monday, August 22nd. Finally, Piper Jaffray Cos. set a $54.00 target price on Pfizer and gave the company a “buy” rating in a research note on Tuesday, August 23rd. Ten analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $38.82.

The stock has a market capitalization of $210.36 billion and a PE ratio of 30.74. The company has a 50 day moving average of $35.72 and a 200 day moving average of $33.43.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.02. The firm had revenue of $13.10 billion for the quarter, compared to analysts’ expectations of $13.01 billion. During the same quarter in the prior year, the business earned $0.56 EPS. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. On average, equities analysts predict that Pfizer Inc. will post $2.46 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Thursday, September 1st. Investors of record on Friday, August 5th were paid a dividend of $0.30 per share. The ex-dividend date of this dividend was Wednesday, August 3rd. This represents a $1.20 dividend on an annualized basis and a yield of 3.46%.

A number of hedge funds recently bought and sold shares of the company. Holderness Investments Co. boosted its stake in Pfizer by 0.8% in the fourth quarter. Holderness Investments Co. now owns 65,817 shares of the biopharmaceutical company’s stock worth $2,125,000 after buying an additional 550 shares during the last quarter. Pettyjohn Wood & White Inc. boosted its stake in Pfizer by 2.7% in the fourth quarter. Pettyjohn Wood & White Inc. now owns 83,918 shares of the biopharmaceutical company’s stock worth $2,709,000 after buying an additional 2,200 shares during the last quarter. Mutual of America Capital Management LLC boosted its stake in Pfizer by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 794,289 shares of the biopharmaceutical company’s stock worth $25,640,000 after buying an additional 3,766 shares during the last quarter. Afam Capital Inc. boosted its stake in Pfizer by 5.9% in the fourth quarter. Afam Capital Inc. now owns 76,884 shares of the biopharmaceutical company’s stock worth $2,482,000 after buying an additional 4,295 shares during the last quarter. Finally, SNS Financial Group LLC boosted its stake in Pfizer by 9.1% in the fourth quarter. SNS Financial Group LLC now owns 62,206 shares of the biopharmaceutical company’s stock worth $2,008,000 after buying an additional 5,192 shares during the last quarter.

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.